GEMALTO
3.4.2018 07:02:11 CEST | Business Wire | Press release
Gemalto (Euronext NL0000400653 GTO), the world leader in digital security, today announced that SafeNet KeySecure has been validated for use with the latest release of NetApp® Volume Encryption (NVE) data management solution. As a result, NetApp customers do not need to encrypt the entire disk drive; they can choose to encrypt granularly at the volume level without the need and additional cost of purchasing self encrypting drives (SEDs), while retaining key benefits such as centralized key management and access control, better compliance, and high availability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180402005033/en/
Data privacy and data security continues to be a key focus for organizations, especially in light of industry compliance standards such as US health standard (HIPAA) or payment card standard (PCI-DSS) and the EU’s General Data Protection Regulation (GDPR ). SafeNet KeySecure centralizes cryptographic processing, security policy and key management, while offering NetApp customers the ability to store and manage encryption keys centrally and separately, away from the encrypted data ensuring security and facilitating compliance.
“Data has become one of the most valuable assets for organizations, but as with anything with value, criminals are determined to get their hands on it,” said Todd Moore, Gemalto Senior Vice President for Encryption Products. “With legislation forcing companies to reveal breaches such as the GDPR, which is due to come into effect in May, there will be nowhere for organizations to hide. This increase in attention means that they must find a way to control who has access to their data and ensure they’re putting in the necessary tools to protect it.”
The Gemalto SafeNet KeySecure solution builds on the NetApp Data Fabric software approach, which simplifies and integrates data management across the cloud and on premises to accelerate digital transformation. On top of having more granular data encryption and keeping keys separate, customers will have the freedom to choose any storage media, have flexible deployment options, audit trails, separation of duties and ecosystem support.
“The NetApp Alliance Partner Program enables us to join forces with the best and brightest in the industry, to address the storage and data infrastructure needs of today’s complex enterprise environments,” said Deepak Visweswaraiah, Senior Vice President, Manageability Products and Solutions Group, at NetApp. “As a result of working with the world leader in digital security, we can now offer our customers peace-of-mind that their data is safe and compliant.”
For more information on Gemalto SafeNet KeySecure:
- Read this blog: Benefits of External Key Management for Storage
- Download the SafeNet KeySecure and SafeNet Virtual KeySecure product briefs
About Gemalto
Gemalto (Euronext NL0000400653 GTO) is the global leader in digital security , with 2017 annual revenues of €3 billion and customers in over 180 countries. We bring trust to an increasingly connected world.
From secure software to biometrics and encryption, our technologies and services enable businesses and governments to authenticate identities and protect data so they stay safe and enable services in personal devices, connected objects, the cloud and in between.
Gemalto’s solutions are at the heart of modern life, from payment to enterprise security and the internet of things. We authenticate people, transactions and objects, encrypt data and create value for software – enabling our clients to deliver secure digital services for billions of individuals and things.
Our 15,000 employees operate out of 114 offices, 40 personalization and data centers, and 35 research and software development centers located in 47 countries.
For more information visit www.gemalto.com , or follow @gemalto on Twitter.
NETAPP, the NETAPP logo, and the marks listed at http://www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180402005033/en/
Contact:
Gemalto media contacts:
Tauri Cox
North America
+1
512 257 3916
tauri.cox@gemalto.com
or
Sophie
Dombres
Europe Middle East & Africa
+33 4 42 55 36 57 38
sophie.dombres@gemalto.com
or
Jaslin
Huang
Asia Pacific
+65 6317 3005
jaslin.huang@gemalto.com
or
Enriqueta
Sedano
Latin America
+52 5521221422
enriqueta.sedano@gemalto.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HTEC Research: Only One in Three Healthcare Organizations is Ready to Scale AI28.4.2026 15:22:00 CEST | Press release
Healthcare and life sciences leaders are advancing AI with caution—fragmentation, capability gaps, and execution challenges are slowing enterprise-wide impact AI is already embedded across healthcare and life sciences. Most organizations are deploying it, and confidence in its potential is high. Yet for many, the real challenge is only just beginning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428872907/en/ HTEC, a global AI‑first provider of software and hardware design and engineering services, today released new research based on a global survey of 253 C-level HLS executives across the United States, United Kingdom, Germany, Spain, Saudi Arabia, and the UAE. AI is already embedded across healthcare and life sciences. Most organizations are deploying AI, and confidence in its potential is high. Yet for many, the real challenge is only just beginning. HTEC, a global AI‑first provider of software and hardware design a
JPMorganChase Named First-Ever Global Banking Partner of the Olympic Games28.4.2026 15:00:00 CEST | Press release
International Olympic Committee and JPMorganChase Announce Landmark Global Olympic Partnership The International Olympic Committee (IOC) and JPMorganChase today announced a landmark Worldwide Olympic Partnership, making JPMorganChase the first Global Banking Partner in Olympic history. The partnership includes the Los Angeles 2028 Olympic and Paralympic Games (LA28 Games) and the French Alps 2030 Olympic and Paralympic Winter Games. The firm has also reached an agreement with LA28 to become the Official Bank of Team USA and LA28, and a Founding Partner of the LA28 Games. The partnership reflects a shared commitment to ambition and excellence, and places athletes and communities at its core. Kirsty Coventry, President of the IOC, commented: “JPMorganChase is the first Global Partner from the banking sector in Olympic history, and we are proud to welcome them to the Worldwide Olympic Partner programme. This partnership reflects our shared values of ambition, excellence and will support t
BlueSnap, Powered by Payroc, Launches Local Acquiring in New Zealand to Boost Approval Rates and Reduce Cross-Border Costs28.4.2026 15:00:00 CEST | Press release
BlueSnap, powered by Payroc, today announced the availability of local acquiring in New Zealand, expanding its global payment orchestration capabilities and enabling businesses to process transactions domestically. Local acquiring allows businesses with a legal entity in New Zealand to process payments through domestic acquiring banks rather than routing transactions cross-border. This helps increase authorization rates, reduce payment failures, and lower transaction costs, critical factors for businesses selling into the region. Why Local Acquiring in New Zealand Matters For B2B and B2C businesses operating globally, cross-border payments often lead to higher fees and lower approval rates. Building local acquiring infrastructure independently requires managing multiple bank relationships, compliance, and integrations, making it costly and complex. BlueSnap simplifies this by providing local acquiring through a single platform, allowing businesses with a legal entity in New Zealand to
Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder28.4.2026 14:42:00 CEST | Press release
Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414145279/en/ Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right) Overactive bladder affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is desi
Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 14:28:00 CEST | Press release
CTIBIOTECH™, a leading innovator in advanced human tissue engineering, proudly announces CTIONCOTEST™ platform is awarded Major Bpifrance Funding to Industrialize 3D Bioprinted Cancer Models CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the pla
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
